DBV Technologies Competitors

DBV Technologies (NASDAQ:DBVT) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Profitability

This table compares DBV Technologies and Kymera Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares DBV Technologies and Kymera Therapeutics' revenue, earnings per share (EPS) and valuation.

Kymera Therapeutics has lower revenue, but higher earnings than DBV Technologies.

Analyst Recommendations

This is a summary of current ratings and target prices for DBV Technologies and Kymera Therapeutics, as provided by MarketBeat.com.

DBV Technologies presently has a consensus target price of $7.0714, suggesting a potential upside of 40.87%. Kymera Therapeutics has a consensus target price of $50.3333, suggesting a potential upside of 9.75%. Given DBV Technologies' higher probable upside, equities research analysts clearly believe DBV Technologies is more favorable than Kymera Therapeutics.

Insider & Institutional Ownership

32.5% of DBV Technologies shares are owned by institutional investors. Comparatively, 37.8% of Kymera Therapeutics shares are owned by institutional investors. 15.3% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BioCryst Pharmaceuticals (NASDAQ:BCRX) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Volatility & Risk

BioCryst Pharmaceuticals has a beta of 3.03, suggesting that its stock price is 203% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 2.91, suggesting that its stock price is 191% more volatile than the S&P 500.

Insider and Institutional Ownership

72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.5% of DBV Technologies shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 15.3% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares BioCryst Pharmaceuticals and DBV Technologies' top-line revenue, earnings per share and valuation.

BioCryst Pharmaceuticals has higher revenue and earnings than DBV Technologies. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioCryst Pharmaceuticals and DBV Technologies' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for BioCryst Pharmaceuticals and DBV Technologies, as reported by MarketBeat.com.

BioCryst Pharmaceuticals currently has a consensus price target of $11.3750, indicating a potential upside of 4.17%. DBV Technologies has a consensus price target of $7.0714, indicating a potential upside of 40.87%. Given DBV Technologies' higher probable upside, analysts plainly believe DBV Technologies is more favorable than BioCryst Pharmaceuticals.

Summary

BioCryst Pharmaceuticals beats DBV Technologies on 8 of the 14 factors compared between the two stocks.

DBV Technologies (NASDAQ:DBVT) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Valuation and Earnings

This table compares DBV Technologies and bluebird bio's gross revenue, earnings per share and valuation.

DBV Technologies has higher earnings, but lower revenue than bluebird bio. DBV Technologies is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for DBV Technologies and bluebird bio, as provided by MarketBeat.com.

DBV Technologies presently has a consensus target price of $7.0714, indicating a potential upside of 40.87%. bluebird bio has a consensus target price of $68.4667, indicating a potential upside of 145.05%. Given bluebird bio's stronger consensus rating and higher probable upside, analysts plainly believe bluebird bio is more favorable than DBV Technologies.

Profitability

This table compares DBV Technologies and bluebird bio's net margins, return on equity and return on assets.

Institutional and Insider Ownership

32.5% of DBV Technologies shares are held by institutional investors. Comparatively, 94.3% of bluebird bio shares are held by institutional investors. 15.3% of DBV Technologies shares are held by insiders. Comparatively, 3.6% of bluebird bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

DBV Technologies has a beta of 2.91, suggesting that its stock price is 191% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500.

Summary

DBV Technologies beats bluebird bio on 8 of the 14 factors compared between the two stocks.

DBV Technologies (NASDAQ:DBVT) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Institutional and Insider Ownership

32.5% of DBV Technologies shares are held by institutional investors. Comparatively, 93.1% of Vericel shares are held by institutional investors. 15.3% of DBV Technologies shares are held by company insiders. Comparatively, 4.3% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares DBV Technologies and Vericel's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares DBV Technologies and Vericel's top-line revenue, earnings per share and valuation.

Vericel has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

DBV Technologies has a beta of 2.91, suggesting that its share price is 191% more volatile than the S&P 500. Comparatively, Vericel has a beta of 3.11, suggesting that its share price is 211% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for DBV Technologies and Vericel, as reported by MarketBeat.com.

DBV Technologies currently has a consensus price target of $7.0714, suggesting a potential upside of 40.87%. Vericel has a consensus price target of $49.00, suggesting a potential upside of 21.26%. Given DBV Technologies' higher possible upside, equities analysts plainly believe DBV Technologies is more favorable than Vericel.

Summary

Vericel beats DBV Technologies on 10 of the 14 factors compared between the two stocks.

DBV Technologies (NASDAQ:DBVT) and Scholar Rock (NASDAQ:SRRK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Institutional and Insider Ownership

32.5% of DBV Technologies shares are held by institutional investors. Comparatively, 61.9% of Scholar Rock shares are held by institutional investors. 15.3% of DBV Technologies shares are held by company insiders. Comparatively, 24.6% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for DBV Technologies and Scholar Rock, as reported by MarketBeat.

DBV Technologies presently has a consensus target price of $7.0714, suggesting a potential upside of 40.87%. Scholar Rock has a consensus target price of $61.60, suggesting a potential upside of 21.74%. Given DBV Technologies' higher probable upside, equities research analysts plainly believe DBV Technologies is more favorable than Scholar Rock.

Profitability

This table compares DBV Technologies and Scholar Rock's net margins, return on equity and return on assets.

Risk & Volatility

DBV Technologies has a beta of 2.91, suggesting that its share price is 191% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.

Valuation & Earnings

This table compares DBV Technologies and Scholar Rock's top-line revenue, earnings per share (EPS) and valuation.

Scholar Rock has higher revenue and earnings than DBV Technologies. Scholar Rock is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Scholar Rock beats DBV Technologies on 8 of the 14 factors compared between the two stocks.

DBV Technologies (NASDAQ:DBVT) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Insider & Institutional Ownership

32.5% of DBV Technologies shares are owned by institutional investors. Comparatively, 8.5% of Ocugen shares are owned by institutional investors. 15.3% of DBV Technologies shares are owned by insiders. Comparatively, 3.5% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares DBV Technologies and Ocugen's revenue, earnings per share (EPS) and valuation.

Ocugen has lower revenue, but higher earnings than DBV Technologies. Ocugen is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for DBV Technologies and Ocugen, as reported by MarketBeat.

DBV Technologies presently has a consensus price target of $7.0714, indicating a potential upside of 40.87%. Ocugen has a consensus price target of $4.80, indicating a potential downside of 46.49%. Given DBV Technologies' higher probable upside, research analysts plainly believe DBV Technologies is more favorable than Ocugen.

Profitability

This table compares DBV Technologies and Ocugen's net margins, return on equity and return on assets.

Risk and Volatility

DBV Technologies has a beta of 2.91, meaning that its share price is 191% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.56, meaning that its share price is 256% more volatile than the S&P 500.

Summary

DBV Technologies beats Ocugen on 7 of the 11 factors compared between the two stocks.